Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 12, 2027

Study Completion Date

December 12, 2027

Conditions

Neuroblastoma (NB)Desmoplastic Small Round Cell Tumor (DSRCT)

Interventions

BIOLOGICAL

CART therapy

GD2/B7H3 CAR T-cell therapy

Trial Locations (3)

RECRUITING

Shanghai YaKe Biotechnology Ltd., Shanghai

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Dongguan Taixin Hospital, Dongguan

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

collaborator

Dongguan Taixin Hospital

UNKNOWN

lead

Sun Yat-sen University

OTHER